SCHEMBL392126

SCHEMBL392126

O=S(=O)(O)c1cc(S(=O)(=O)O)c2cc(S(=O)(=O)O)ccc2c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP6 P55212 4/20 0.68
HSD17B10 Q99714 4/20 0.68
ALDH1A1 P00352 4/20 0.68
CYP2C9 P11712 3/20 0.68
CYP2C19 P33261 2/20 0.68
NT5E P21589 3/20 0.54
NSD2 O96028 3/20 0.50
ENPP2 Q13822 1/20 0.47
PTPN11 Q06124 3/20 0.46
DUSP3 P51452 2/20 0.46
PTPN5 P54829 2/20 0.46
CASP7 P55210 1/20 0.46
SNCA P37840 2/20 0.46
SUMO2 P61956 1/20 0.46
SUMO1 P63165 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP2 Q9HC62 1/20 0.46
PRMT1 Q99873 1/20 0.42
CYP1A2 P05177 2/20 0.42
PTPRC P08575 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31398449 1.00 CASP6 (0.68) CASP6HSD17B10ALDH1A1CYP2C9CYP2C19
SCHEMBL31398448 1.00 CASP6 (0.68) CASP6HSD17B10ALDH1A1CYP2C9CYP2C19
SCHEMBL5292706 1.00 CASP6 (0.68) CASP6HSD17B10ALDH1A1CYP2C9CYP2C19
SCHEMBL22631256 0.89 CASP6 (0.56) CASP6HSD17B10ALDH1A1CYP2C9CYP2C19
SCHEMBL30675695 0.89 CASP6 (0.56) CASP6HSD17B10ALDH1A1CYP2C9CYP2C19
Naphthalene Trisulfonate SCHEMBL306176 0.88 CASP6 (0.58) CASP6HSD17B10ALDH1A1CYP2C9CYP2C19
Naphthalene Trisulfonate SCHEMBL29431498 0.88 CASP6 (0.58) CASP6HSD17B10ALDH1A1CYP2C9CYP2C19
Naphthalene Trisulfonate SCHEMBL305166 0.88 CASP6 (0.58) CASP6HSD17B10ALDH1A1CYP2C9CYP2C19
SCHEMBL21854252 0.88 CASP6 (0.54) CASP6HSD17B10ALDH1A1CYP2C9CYP2C19
Naphthalene Trisulfonate SCHEMBL23931196 0.86 CASP6 (0.56) CASP6HSD17B10ALDH1A1CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2053098-B1 Ink composition, ink cartridge, inkjet recording method, and recorded matter SEIKO EPSON CORP (JP) 2014-01-22 EP claimed
US-8100020-B2 Compliant and wireless health monitoring sensors for composite structures Lumimove, Inc., a Missouri Corporation (US) 2012-01-24 US claimed
JP-2011525240-A 2011-09-15 JP claimed
EP-2297559-A2 COMPLIANT AND WIRELESS HEALTH MONITORING SENSORS FOR COMPOSITE STRUCTURES Lumimove, Inc., Dba Crosslink (US) 2011-03-23 EP claimed
CN-1831054-B Ink composition, ink cartridge, inkjet recording method, and recorded matter SEIKO EPSON CORP 2010-06-16 CN claimed
US-7732625-B2 Colorant compounds XEROX CORPORATION (US) 2010-06-08 US claimed
US-20100095781-A1 COMPLIANT AND WIRELESS HEALTH MONITORING SENSORS FOR COMPOSITE STRUCTURES LUMIMOVE, INC., D/B/A CROSSLINK (US) 2010-04-22 US claimed
WO-2009155367-A2 COMPLIANT AND WIRELESS HEALTH MONITORING SENSORS FOR COMPOSITE STRUCTURES LUMIMOVE, INC., D/B/A CROSSLINK (US) 2009-12-23 WO claimed
EP-2053098-A1 Ink composition, ink cartridge, inkjet recording method, and recorded matter SEIKO EPSON CORPORATION (JP) 2009-04-29 EP claimed
EP-1700889-B1 Ink composition, ink cartridge, inkjet recording method, and recorded matter SEIKO EPSON CORP (JP) 2009-03-11 EP claimed
EP-1700889-A1 Ink composition, ink cartridge, inkjet recording method, and recorded matter SEIKO EPSON CORPORATION (JP) 2006-09-13 EP claimed
CN-1831054-A Ink composition, ink cartridge, inkjet recording method, and recorded matter SEIKO EPSON CORP (JP) 2006-09-13 CN claimed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 US claimed
US-6036833-A PLATING WITH PERIODIC REVERSE PULSES AND A SULFONATED NAPHTHALENE ADDITIVE IN BATH CONTAINING NICKEL OR COBALT CHLORIDES AND/OR SULFATES YIELDS PLATINGS FREE OF INTERNAL STRESS TANG PETER TORBEN (DK) 2000-03-14 US claimed
EP-0820284-B1 BIOLOGICALLY ACTIVE UREIDO DERIVATIVES USEFUL IN THE TREATMENT OF MULTIPLE SCLEROSIS PHARMACIA & UPJOHN SPA (IT) 2000-02-02 EP claimed
EP-0820284-A1 BIOLOGICALLY ACTIVE UREIDO DERIVATIVES USEFUL IN THE TREATMENT OF MULTIPLE SCLEROSIS PHARMACIA & UPJOHN S.p.A. (IT) 1998-01-28 EP claimed
WO-1997028796-A1 BIOLOGICALLY ACTIVE UREIDO DERIVATIVES USEFUL IN THE TREATMENT OF MULTIPLE SCLEROSIS PHARMACIA & UPJOHN S.P.A. (IT) 1997-08-14 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 CASP6 2660/4885HSD17B10 2219/4885ALDH1A1 1569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.